Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Oral drug cut viral respiratory tract infections in elderly

Key clinical point: A once-daily oral drug safely cut respiratory tract infections.

Major finding: During 16 weeks of treatment, the incidence of viral respiratory tract infections was 30.6% lower compared with placebo.

Study details: A phase 2 multicenter, placebo-controlled study of 952 subjects, including 356 randomized to the best-performing dosage.

Disclosures: Dr. Mannick is a cofounder and chief medical officer of resTORbio, the company developing RTB101.

Citation:

REPORTING FROM IDWEEK 2019